FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-03-12

Price

$14.37

+0.00%

Score6.0Priority

Signals5/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.6xvs 20d avg

Analysis

Amicus Therapeutics (FOLD) is trading with exceptionally tight price action because it is currently the subject of an all-cash $14.50 per share acquisition by BioMarin Pharmaceutical. The exceptionally strong technical signals (ALPHA_MALE, QUIET_STORM) and ultra-low 2.1% realized volatility are simply reflecting merger arbitrage dynamics as the stock pins near the buyout price. Furthermore, the prevailing RISK_OFF geopolitical regime is irrelevant to FOLD's idiosyncratic trajectory; tight high-yield credit spreads (0.88%) indicate zero financing stress, giving the market absolute conviction that this definitive M&A deal will successfully close.

Fired Signals

ALPHA MALEQUIET STORMGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKSELLER FATIGUE

Key Takeaways

Actionable Thesis: FOLD is a pure merger arbitrage play, offering a fixed, low-risk yield up to the $14.50 all-cash acquisition price by BioMarin.
Key Risk: The only material risk to the downside is a highly unlikely antitrust block or regulatory delay that breaks the deal terms.
What to Watch: Monitor Hart-Scott-Rodino (HSR) antitrust clearance and the final closing timeline following the recent shareholder approval.

← Back to 2026-03-12 View Full FOLD History →Yahoo Finance &nearr;